Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06350175
Other study ID # 2212697123
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date June 2024
Est. completion date June 2025

Study information

Verified date May 2024
Source West Virginia University
Contact Bradley End, MD
Phone 304 293 9565
Email bradley.end@hsc.wvu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine the effectiveness of ED initiated NRT on tobacco cessation point abstinence rates as reported by patients at 2 weeks and 1 month post randomization, and continued abstinence rates at 3 months compared to standard of care therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date June 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Current daily use cigarettes greater than or equal to ½ pack per day - Stable for discharge from the ED - Able and willing to complete telephone/electronic follow up at scheduled intervals - Reported English speaking Exclusion Criteria: - Patients enrolled in specific health insurance plans (PEIA, The Health Plan or Medicaid medical insurance) - WVU students - Medically unstable patients - Patients with clinical decompensation or who are admitted to the hospital - Patients who are discharged to residential treatment facilities for detoxification - Uncontrolled psychiatric disorder or psychiatric emergency - Individuals who are unable to provide consent - Incarcerated individuals - Language barrier - Currently pregnant or attempting to become pregnant - Presenting for evaluation of sexual assault - Known allergy or previous intolerance to nicotine replacement therapy

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Nicotine Replacement Therapy Agent
The NRT Agents-- 21mg nicotine patches (x14) and 2 mg nicotine lozenges (~210).
Other:
West Virginia Quit Line
Instructional Pamphlets and contact information for the WV QL. A telehealth line set up to assist people of WV to quit smoking.

Locations

Country Name City State
United States West Virginia University Morgantown West Virginia

Sponsors (1)

Lead Sponsor Collaborator
West Virginia University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Continued Abstinence Rate (2 weeks) Percentage of subjects who self-report continued abstinence in tobacco use at 2 weeks from initial dose given during the ED visit. 2 Weeks post initial dose
Primary Percentage of Continued Abstinence Rate (1 month) Percentage of subjects who self-report continued abstinence in tobacco use at 1 month from initial dose given during the ED visit. 1 Month post initial dose
Primary Percentage of Continued Abstinence Rate (3 months) Percentage of subjects who self-report continued abstinence in tobacco use at 3 months from initial dose given during the ED visit. 3 Months post initial dose
Primary Patient Health Questionnaire 2 (Baseline) A validated instrument to assess the frequency of depression and anhedonia screen for depression, scores can range from 0 to 6, with each item scored from 0 (not at all) to 3 (nearly every day). Scores greater than or equal to typically indicate depression. Baseline
Primary Patient Health Questionnaire 2 (3 months from baseline) A validated instrument to assess the frequency of depression and anhedonia screen for depression, scores can range from 0 to 6, with each item scored from 0 (not at all) to 3 (nearly every day). Scores greater than or equal to typically indicate depression. 3 months from baseline
Primary Heaviness of Smoking Index (Baseline) A validated measure used to determine the level of nicotine addiction, with a scale of 0-6 (3 indicates moderate addiction, >5 is severe) Baseline
Primary Heaviness of Smoking Index (3 months from baseline) A validated measure used to determine the level of nicotine addiction, with a scale of 0-6 (3 indicates moderate addiction, >5 is severe) 3 months from baseline
Primary Richmond Test (Baseline) A validated instrument to assess motivation to quit smoking. This is scored on a 0-10 scale with 5-6 indicating moderate motivation to quit and 7+ indicating strong motivation to quit. Baseline
Primary Richmond Test (3 months from baseline) A validated instrument to assess motivation to quit smoking. This is scored on a 0-10 scale with 5-6 indicating moderate motivation to quit and 7+ indicating strong motivation to quit. 3 months from baseline
See also
  Status Clinical Trial Phase
Withdrawn NCT02432066 - Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions Phase 2
Completed NCT03960138 - Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Completed NCT04646668 - Comparative Abuse Liability Among African American and White Smokers N/A
Completed NCT02560324 - Effect of Ramelteon on Smoking Abstinence Phase 2
Completed NCT02347605 - Medicinal Nicotine for Preventing Cue Induced Craving N/A
Terminated NCT01800500 - Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers N/A
Completed NCT01428310 - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke Phase 1
Completed NCT01442753 - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth N/A
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Completed NCT01625767 - Tobacco Approach Avoidance Training for Adolescent Smokers-1 Phase 2
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT01337817 - A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers Phase 1
Completed NCT00967005 - N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Phase 2
Active, not recruiting NCT00751660 - Screening Methods in Finding Lung Cancer Early in Current or Former Smokers N/A
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Completed NCT00664261 - Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking N/A
Completed NCT00158158 - Effectiveness of Reducing Smoking in Facilitating Smoking Cessation in Adolescents - 2 Phase 2/Phase 3
Completed NCT00158145 - Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2 Phase 2
Completed NCT01213524 - Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia Phase 2